Welcome to our dedicated page for NIKA PHARMACEUTICALS news (Ticker: NIKA), a resource for investors and traders seeking the latest updates and insights on NIKA PHARMACEUTICALS stock.
NIKA Pharmaceuticals Inc. is a leading pharmaceutical company dedicated to developing innovative treatments for various diseases. With a focus on research and development, NIKA is committed to improving global healthcare through groundbreaking therapies. The company's recent achievements include FDA approvals for cutting-edge medications and strategic partnerships with top healthcare providers.
Nika Pharmaceuticals (OTCMKTS: NIKA) has signed a distribution agreement for Nigeria with I.Conntact-Connect on June 11, 2024. This partnership targets a market of 229 million people with a 2.1% HIV prevalence rate. Under the agreement, NIKA will receive €1,980 per ITV-1 set, with two sets required per treatment, potentially generating €7.9 billion in revenue.
The deal aims to address Nigeria's HIV epidemic, where 190,950 new HIV/AIDS infections occur annually, including 41,000 cases among children with access to therapies. CEO Dimitar Savov announced plans to open a satellite office in Nigeria to serve as a hub for West Africa, emphasizing the country's strategic importance to NIKA.
Nika Pharmaceuticals (NIKA) announced plans to become a sustainable business, focusing on pharmaceutical production and profitability. Key developments include constructing three factories for injection drugs, tablets, and dietary supplements.
On May 9, 2024, NIKA acquired a production building valued at $2,045,209 for an injection drug factory, expected to finish by December 31, 2024. A new vial production line is set to produce 18,000 vials per hour, with an annual capacity of 3.5 million sets of ITV-1, generating significant profits.
NIKA's Joint Business Agreement with Immunotech Laboratories BG facilitates the production and distribution of ITV-1, an AIDS treatment, expected to start at 30% capacity in 2025, aiming for 90% by 2026. Distribution agreements cover UAE, Ukraine, Iraq, Jordan, and Syria, with ongoing negotiations for more territories.
NIKA's portfolio includes generic drugs and dietary supplements, with ongoing development and market expansion plans. A comprehensive five-year business plan is being prepared to outline future growth.
Nika Pharmaceuticals, Inc. (NIKA) has acquired a production building and land valued at $2,045,209 in Sofia Province, Bulgaria. The company became the 99.99% owner of Nika Europe, , which holds the production building and land. The facility will house laboratories and a manufacturing facility for drug production. Construction is underway, with plans to begin production in January 2025.
FAQ
What is the current stock price of NIKA PHARMACEUTICALS (NIKA)?
What is the market cap of NIKA PHARMACEUTICALS (NIKA)?
What is NIKA Pharmaceuticals Inc. known for?
What are some recent achievements of NIKA Pharmaceuticals Inc.?
What is the focus of NIKA Pharmaceuticals Inc.'s research and development efforts?
How does NIKA Pharmaceuticals Inc. contribute to global healthcare?
What sets NIKA Pharmaceuticals Inc. apart from other pharmaceutical companies?
What type of medications does NIKA Pharmaceuticals Inc. specialize in?
How does NIKA Pharmaceuticals Inc. contribute to medical advancements?
What is the vision of NIKA Pharmaceuticals Inc.?
What are some upcoming projects for NIKA Pharmaceuticals Inc.?
How does NIKA Pharmaceuticals Inc. prioritize patient care?
